Clinical and Hematological Features of Acute Leukemia in Pediatric and Adult Patients at a Tertiary Care Hospital Lahore
DOI:
https://doi.org/10.59058/et455774Keywords:
Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hematological Malignancy, Sudan Black-B, FAB ClassificationAbstract
Background and Objectives: Terpinen-4-ol (T4-ol) is a monoterpene derivative of essential oil which has
many anti- inflammatory, bactericidal and antifungal activities and is safe as compared to other treatment
options available. Our study's objectives were to analyze the effects of different concentrations of Terpinen4-ol on apoptosis of cell lines.
Methods: This in vitro experimental study was conducted at the IMBB Department, University of Lahore,
Lahore Pakistan, from October 2022 to March 2023. Study treatment was divided into four groups: negative
control (normal cell line), positive control (cisplatin) Terpinen-4-ol (experimental group) and vehicle control
(DMSO). In order to culture cells cryovials were thawed and then cells were cultured in T75 flasks. To assess
the cell viability MTT assay was used. Bioassay technology laboratory ELISA kit was used to evaluate
inflammation and apoptosis. Graph Pad prism was used to perform statistical analysis. The data was
analyzed using one- way analysis of variance (ANOVA) with bonferroni comparison within groups. P ≤ 0.05
was considered statistically significant.
Results: When compared to the control group, the treated lines showed more apoptotic changes. P-value was
≤ 0.05.
Conclusion: In this study we have observed anticancer effects of T4-ol against GBM cell line by observing
p53 induced apoptosis.
Key Words: Terpinen-4-ol (T-4-ol), Glioblastoma (GBM), apoptosis, MTTand Crystal Voilet assay.
References
1. Shahab F, Raziq F. Clinical presentations of acute
leukemia. J Coll Physicians Surg Pak. 2014 Jul
1;24(7):472-6.
2. Mushtaq N, Fadoo Z, Naqvi A. Childhood acute
lymphoblastic leukaemia: Experience from a single
tertiary care facility of Pakistan. Journal of Pakistan
Medical Association. 2013; 63(11):1399.
3. Ahmad I, Ghafoor T, Ullah A, Naz S, Tahir M,
Ahmed S, Arshad A, Ali A, Khattack TA, Batool F.
Pediatric Acute Lymphoblastic Leukemia: Clinical
Characteristics, Treatment Outcomes, and
Prognostic Factors: 10 Years' Experience From a
Low-and Middle-Income Country. JCO Global
Oncology. 2023 Jun; 9:e2200288
4. Ranan K P, Rawand PS, Nawsherwan S M. Clinical
and haematological parameters in adult AML
patients: a four year experience at Nanakaly Hospital
for blood diseases.
5. Bennett JM, Catovsky D, Daniel MT, Flandrin G,
Galton DA, Gralnick HR, et al. Proposals for the
classification of the acute leukaemias. FrenchAmerican-British (FAB) co-operative group. Br J
Haematol 1976; 33: 451-8
6. Singh G, Parmar P, Kataria SP, Singh S, Sen R.
Spectrum of acute and chronic leukemia at a tertiary
care hospital, Haryana, India
7. Kulsoom B, Shamsi TS, Ahmed N, Hasnain SN.
Clinical presentation of acute myeloid
leukaemia—A decade-long institutional follow-up.
changes. 2017;39:7-2.
8. Khalid A, Ahmed M, Hasnain S. Biochemical and
Hema tologi c Profil e s in B-Ce ll Acut e
Lymphoblastic Leukemia Children. Journal of
Pediatric Hematology/Oncology. 2023 Oct
1;45(7):e867-72.
9. Mushtaq N, Fadoo Z, Naqvi A. Childhood acute
iymphoblastic leukaemia: Experience from a single
tertiary care facility of Pakistan. Journal of Pakistan
Medical Association. 2013;63(11):1399.
10. Death analysis of childhood Acute Lymphoblastic
Leukaemia; experience at Shaukat Khanum
Memorial Cancer Hospital and Research Centre,
Pakistan
11. Mishra K, Kumar S, Ninawe S, Bahl R, Meshram A,
Singh K, Jandial A, Sahu KK, Sandal R, Khera S,
Yanamandra U. The clinical profile, management,
and outcome of febrile neutropenia in acute myeloid
leukemia from resource constraint settings.
Therapeutic Advances in Infectious Disease. 2021
Aug;8:20499361211036592.
12. Khalid A, Ahmed M, Hasnain S. Biochemical and
Hematologic profiles in B-Cell acute lymphoblastic
leukemia children. Journal of Pediatric
Hematology/Oncology. 2023 Oct 1;45(7):e867-72.
13. Ibrahim RM, Idrees NH, Younis NM. Epidemiology
of leukemia among children in Nineveh Province,
Iraq. Rawal Medical Journal. 2023 Mar 3;48(1):137.
14. Jaime-Pérez JC, García-Arellano G, Herrera-Garza
JL, Marfil-Rivera LJ, Gómez-Almaguer D.
Revisiting the complete blood count and clinical
findings at diagnosis of childhood acute
lymphoblastic leukemia: 10-year experience at a
single center. Hematology, transfusion and cell
therapy. 2019 Apr 15;41(1):57-61.
15. Siddaiahgari SR, Awaghad MA, Latha MS. Clinical,
immunophenotype and cytogenetic profile of acute
lymphoblastic leukemia in children at tertiary health
care centre in India. Muller Journal of Medical
Sciences and Research. 2015 Jul 1;6(2):112-8.
16. Khalid A, Ahmed M, Hasnain S. Biochemical and
Hematologic profiles in B-Cell acute lymphoblastic
leukemia children. Journal of Pediatric
Hematology/Oncology. 2023 Oct 1;45(7):e867-72.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Asma Akhtar, Rabia Ahmad, Masuma Ghazanfar, Shizra Kaleemi, Sabeen Fatima (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- Non-Commercial — You may not use the material for commercial purposes .
- No-Derivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
